Gross Margin

With a new HQ and $2M in contracts, Taoping is leveraging AI and government policy to modernize China's aging elevators, but faces investor scrutiny.

Ethical food leader Vital Farms heads to the ICR Conference with record profits and a $2B goal, ready to prove its model can win against new competition.

Eightco Holdings bets big on its own stock with a $125M buyback, banking on its Worldcoin treasury and a vision for AI-proof digital identity.

iQSTEL caps a transformational year with a NASDAQ uplist, record revenue, and a strategic pivot to Fintech and Cybersecurity, eyeing a $1B future.

After 100 years, Southeastern Grocers rebrands as The Winn-Dixie Company, focusing on Florida with store remodels and deep community investment.

EUDA Health's new Helixé 2.0 supplement boasts enhanced potency, nano-delivery tech, and Halal certification to capture the booming global wellness market.

With a strong debut on the Hong Kong Stock Exchange, USAS Building System highlights growing investor faith in prefabricated industrial construction.

The cardiac device innovator adds seasoned sales and operations executives to prepare its novel cryoablation technology for the global market.

Chinese insurtech Huize is cutting back on financial reports to focus on strategy, but its latest data shows a complex picture of soaring premiums and slowing new user growth.

Swisslog Healthcare appoints Maria Garces from competitor Omnicell as VP, signaling an aggressive push to innovate and dominate the health tech market.

The newly public logistics firm reports soaring H1 2025 profits and revenue, yet its stock price tells a different, more cautious story.

RPM's strategic acquisition of Dealers Choice Auto Transport signals a major shift, combining enterprise logistics tech with white-glove specialty service.

Precious metals soar in 2025, with silver's 128% surge fueled by geopolitical turmoil, economic fears, and a booming demand from green tech and AI.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

A new study reveals Gen X faces a shocking $400K retirement shortfall, caught between fading pensions and an imperfect 401(k) system. Are they prepared?

The Nasdaq-listed restaurant operator confirms its board and auditor, signaling stability as it navigates a volatile stock performance and dynamic F&B sector.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.